MedTrace Logo

Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

NCT00944385 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-05-27

No results posted yet for this study

Summary

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Conditions

  • Abnormal Aortic Valve

Interventions

DRUG

ulinastatin

Administer 30000U/ulinastatin. Comparison of different dosages of drug.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Younglan Kwak, MD, PhD · Severance Hospital

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944385 on ClinicalTrials.gov